Lexicon director granted options and RSUs

LEXICON PHARMACEUTICALS director Christopher J. Sobecki received new equity awards as part of his compensation.

Rhea-AI Filing Summary

LEXICON PHARMACEUTICALS director Christopher J. Sobecki received new equity awards as part of his compensation. On May 1, 2026, he was granted stock options for 43,478 shares of common stock at an exercise price of $1.61 per share, vesting in three equal annual installments on each of the first three anniversaries of the grant date. He was also granted 35,714 restricted stock units, which vest in full on the first anniversary of the grant date, with each unit representing a contingent right to receive one share of common stock. These are awards from the company rather than open‑market purchases or sales.

Insider Trade Summary

Grant/Award: 79,192 shares

Grant/Award 2 txns

Insider SOBECKI CHRISTOPHER J

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	35,714	$0.00	$0.00
Grant/Award	Stock Option (Right to Buy)	43,478	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units — 35,714 contracts (Direct); Stock Option (Right to Buy) — 43,478 contracts (Direct)

Footnotes (3)

1. F1. Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date.
2. F2. Each restricted stock unit represents a contingent right to receive one share of common stock.
3. F3. Option vests with respect to one third of the shares subject to the option on each of the first three anniversaries of the grant date.

Key Figures

Stock options granted: 43,478 shares Option exercise price: $1.61 per share RSUs granted: 35,714 units +3 more

6 metrics

Stock options granted 43,478 shares Grant dated May 1, 2026 to director Christopher J. Sobecki

Option exercise price $1.61 per share Stock Option (Right to Buy) on Lexicon common stock

RSUs granted 35,714 units Restricted Stock Units granted May 1, 2026

Option expiration May 1, 2036 Expiration date for 43,478 stock options

Options held after grant 43,478 derivative shares Total stock options following transaction for this award

RSUs held after grant 35,714 derivative shares Total restricted stock units following transaction for this award

Key Terms

Restricted stock unit, contingent right, Stock Option (Right to Buy), vests

4 terms

Restricted stock unit financial

"Restricted stock unit vests with respect to 100% of the shares"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

contingent right financial

"Each restricted stock unit represents a contingent right to receive one share"

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

vests financial

"Option vests with respect to one third of the shares"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Lexicon Pharmaceuticals (LXRX) director Christopher Sobecki receive in this Form 4 filing?

Director Christopher J. Sobecki received new equity awards, including stock options and restricted stock units, from Lexicon Pharmaceuticals. These awards are compensation grants, not open‑market trades, and give him potential future ownership in additional common shares if vesting conditions are met.

How many stock options were granted to the Lexicon (LXRX) director and at what price?

Christopher Sobecki was granted stock options covering 43,478 shares of Lexicon common stock at an exercise price of $1.61 per share. These options allow him to buy shares at that price once vested, potentially benefiting if the market price exceeds $1.61.

What are the vesting terms for the Lexicon (LXRX) director’s new stock options?

The stock options granted to Christopher Sobecki vest in three equal annual installments. One third of the 43,478 option shares vest on each of the first three anniversaries of the May 1, 2026 grant date, encouraging multi‑year alignment with shareholder interests.

How many restricted stock units did the Lexicon (LXRX) director receive and how do they work?

Christopher Sobecki received 35,714 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Lexicon common stock, meaning he will receive actual shares once the vesting conditions are satisfied and the award settles.

When do the Lexicon (LXRX) restricted stock units granted to the director vest?

The restricted stock units vest in a single tranche. All 35,714 RSUs vest with respect to 100% of the shares on the first anniversary of the May 1, 2026 grant date, assuming continued service or satisfaction of the plan’s conditions.

Are the transactions in this Lexicon (LXRX) Form 4 open‑market buys or sells?

The transactions reported are equity compensation grants, not open‑market buys or sells. They are classified as grant or award acquisitions, with zero transaction price, reflecting options and restricted stock units awarded by Lexicon rather than trades executed on an exchange.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/04/2026 - 04:57 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SOBECKI CHRISTOPHER J

(Last) (First) (Middle)

2445 TECHNOLOGY FOREST BLVD.

11TH FLOOR

(Street)

THE WOODLANDS TEXAS 77381

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
LEXICON PHARMACEUTICALS, INC. [ LXRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0	05/01/2026		A		35,714		(1)	(2)	Common Stock	35,714	$0	35,714	D
Stock Option (Right to Buy)	$1.61	05/01/2026		A		43,478		(3)	05/01/2036	Common Stock	43,478	$0	43,478	D

Explanation of Responses:

1. Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date.

2. Each restricted stock unit represents a contingent right to receive one share of common stock.

3. Option vests with respect to one third of the shares subject to the option on each of the first three anniversaries of the grant date.

	/s/ Christopher J. Sobecki	05/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)